McKesson Corporation (MCK) Earnings Call Transcripts

McKesson Corporation's Latest Earnings Call - May 12, 2026

In the fourth quarter of fiscal 2026, McKesson Corporation reported strong financial performance, with revenue growth and adjusted operating profit growth exceeding long-range targets. The company achieved an 18% increase in adjusted EPS and a 15% rise in adjusted operating profit, driven by robust performance across its pharmaceutical distribution and specialty segments. Management provided guidance for fiscal 2027, indicating expectations for continued growth, particularly in specialty pharmaceuticals, despite some anticipated revenue fluctuations due to pricing changes in the market.

Reported metrics

Guidance from management

Management expects low to mid-single-digit top line growth in the RxTS segment for fiscal 2027, with strong adjusted operating profit growth. They reiterated confidence in achieving growth rates at the high end of their long-range targets.

What management said

Yes. I think it's something that we'll evaluate. Obviously, we're very early into this particular drug. So we want to learn from this and see what the reception is to this. And over time, if we think that it's going to advance affordability and access. We think that there's going to be receptivity to the additional choice that's available. I'm sure it's something that we'll study, but again, anything that's going to ...

We've seen volatility in commodity prices, fuel prices really over the last 10 years, it's been pretty constant in the business. So I think we do a good job managing through that. We have lots of manufacturing partners that allow us to manage through that. We're -- I think we've done a good job of managing the cost side of it and certainly protecting the margin side of it. So this -- certainly, there's a little more ...

What analysts pressed on

Analysts raised concerns regarding the impact of pricing changes on revenue and the variability in cash flow generation. There were also questions about the profitability of new biosimilars and how they would affect margins in the long term.

Main topics on the call

• Strong Financial Performance — McKesson reported an 18% increase in adjusted EPS and a 15% rise in adjusted operating profit for fiscal 2026, with management stating, "there's a lot of really good momentum in the business." This performance exceeded t...
• Growth in Specialty Pharmaceuticals — Management noted that the Specialty Distribution segment surpassed $100 billion and continues to grow, with GLP-1s generating over $53 billion in revenue, reflecting a growth rate of over 25%. They expect this segment to...
• Impact of Price Changes — Management acknowledged some revenue impacts from manufacturer list price declines, but emphasized that these did not affect gross profit or adjusted operating profit, as they are compensated on a fixed fee-for-service b...
• Biosimilars Strategy — McKesson's entry into the biosimilar market with products like Stimufend reflects a strategic shift aimed at enhancing access and affordability. Management indicated that biosimilars generally offer better margin opportu...

Read the full McKesson Corporation transcript (May 12, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 65 McKesson Corporation earnings call transcripts on record, spanning January 14, 2020 to May 12, 2026. Based on this history, McKesson Corporation reports quarterly. The most recent call on file is dated May 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MCK

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

65

First call

January 14, 2020

Most recent

May 12, 2026

Reporting cadence

quarterly